Product Description
GL-3 Molecule (Prescription Only) – 60mg / 5mL
Triple-Incretin Therapy for Maximum Fat Loss, Appetite Control & Metabolic Optimization
Formulation
GL-3 Core 60
1 × 60mg GL-3 Multi-Dose Vial
Each vial contains:
-
60mg GL-3
-
5mL total volume
-
Concentration: 12mg/mL
Total Package Contents: 60mg GL-3 (5mL Total)
Classification: Prescription Only – Requires Provider Consultation & Approval
What Is GL-3 Therapy?
GL-3 is a prescription triple-incretin therapy that activates three key metabolic pathways:
-
GLP-1 (Glucagon-Like Peptide-1)
-
GIP (Glucose-Dependent Insulinotropic Polypeptide)
-
Glucagon Receptor
By targeting all three receptors simultaneously, GL-3 provides comprehensive metabolic signaling, leading to:
✔ Significant appetite suppression
✔ Accelerated fat loss
✔ Improved insulin sensitivity
✔ Increased energy expenditure
✔ Enhanced metabolic flexibility
✔ Long-term body composition improvements
GL-3 represents the most advanced tier of incretin-based therapy and is typically utilized for patients requiring longer-term, provider-directed metabolic intervention and sustained fat loss.
All GL-3 products require clinical consultation and prescription approval prior to dispensing.
🔬 Key Research-Based Mechanisms
🔥 Triple-Incretin Activation for Superior Fat Loss
Simultaneous activation of GLP-1, GIP, and glucagon receptors enhances satiety and drives adipose tissue reduction.
Jastreboff et al., 2023 (NEJM) – Demonstrated up to 24.2% total body-weight reduction over 48 weeks.
🩸 Improved Glycemic Control & Insulin Sensitivity
Reduces fasting glucose, improves insulin signaling, and lowers HbA1c.
Frias et al., 2023 (Diabetes Care) – Reported HbA1c reductions up to 2.2%.
🧠 Appetite Suppression & Craving Control
Reduces central appetite signaling and food reward pathways.
Killion et al., 2022 – Demonstrated reduced hedonic eating behavior in preclinical models.
🧬 Increased Fat Oxidation & Energy Expenditure
Glucagon receptor activation increases metabolic rate and fat utilization.
Gil-Lozano et al., 2021 – Showed preservation of metabolic rate with increased fat oxidation.
⚕️ Clinical Access & Prescription Protocol
GL-3 therapy requires provider oversight and prescription approval.
✔ Telehealth consultation required prior to dispensing
✔ Labs may be recommended (HbA1c, fasting glucose, lipid panel, CMP)
✔ Individualized dosing and titration plan
✔ Ongoing provider monitoring and follow-up included
💉 Dosing Protocol (GL-3 Core 60)
Total Dose
60mg Total GL-3
Package Contents
1 × 60mg / 5mL vial
Concentration
12mg/mL
Dosing Equivalency
| Units | GL-3 Dose |
|---|---|
| 8 Units | ~1mg |
| 17 Units | ~2mg |
| 25 Units | ~3mg |
| 33 Units | ~4mg |
| 42 Units | ~5mg |
| 50 Units | ~6mg |
| 67 Units | ~8mg |
| 83 Units | ~10mg |
Starting Dose
17 Units Weekly (~2mg)
Titration Strategy (Standard PROPeptides Protocol)
✔ Begin at 17 units weekly
✔ Maintain dose until 2 consecutive weeks of no meaningful weight loss
✔ Increase by approximately 8–9 units (~1mg) when appropriate
✔ If side effects occur, reduce dose by approximately 8–9 units and resume titration after symptoms resolve
Administration
Route: Subcutaneous injection
Preferred Site: Abdomen
Frequency: Once weekly
Ideal Use
The GL-3 Core 60 vial is designed for patients who have advanced beyond starter dosing and are maintaining moderate to higher weekly doses.
Typical utilization:
-
4mg weekly (33 units) = approximately 15 weeks
-
5mg weekly (42 units) = approximately 12 weeks
-
6mg weekly (50 units) = approximately 10 weeks
-
8mg weekly (67 units) = approximately 7–8 weeks
Actual duration varies based on provider-directed titration and individual response.
Program Length
Typically utilized as part of a 3–12 month provider-guided metabolic optimization program with reassessment every 4–8 weeks.
Compatible Stacks
KPV
Supports gut health and inflammation management.
Tesamorelin
May support body composition optimization and visceral fat reduction.
MOTS-C
Supports metabolic efficiency and insulin sensitivity.
GHK-Cu
Supports recovery and tissue support.
📦 What’s Included With Every Order
✔ 1 × 60mg / 5mL GL-3 vial
✔ Insulin syringes & alcohol swabs
✔ Sharps container bag
✔ Printed dosing, titration, storage, and injection guide
✔ Ongoing access to licensed prescribing provider
✔ Free telemedicine consultation through Arizona Sports Medicine
📧 Need Assistance?
480-400-6225
🛡️ Maximum Potency. Triple-Pathway Precision. Clinical Oversight.
GL-3 Core 60 is designed for patients seeking long-term metabolic optimization with the convenience of a high-capacity multi-dose vial. Through triple-incretin activation and provider-guided dosing, GL-3 supports meaningful fat loss, appetite control, improved insulin sensitivity, and sustained body composition improvements.
Commit to GL-3 Core 60 for advanced metabolic support, extended supply, and provider-guided weight loss optimization.
Directions For Use
GL-3 Molecule (Prescription Only) – 60mg / 5mL
Triple-Incretin Therapy for Maximum Fat Loss, Appetite Control & Metabolic Optimization
Formulation
GL-3 Core 60
1 × 60mg GL-3 Multi-Dose Vial
Each vial contains:
-
60mg GL-3
-
5mL total volume
-
Concentration: 12mg/mL
Total Package Contents: 60mg GL-3 (5mL Total)
Classification: Prescription Only – Requires Provider Consultation & Approval
What Is GL-3 Therapy?
GL-3 is a prescription triple-incretin therapy that activates three key metabolic pathways:
-
GLP-1 (Glucagon-Like Peptide-1)
-
GIP (Glucose-Dependent Insulinotropic Polypeptide)
-
Glucagon Receptor
By targeting all three receptors simultaneously, GL-3 provides comprehensive metabolic signaling, leading to:
✔ Significant appetite suppression
✔ Accelerated fat loss
✔ Improved insulin sensitivity
✔ Increased energy expenditure
✔ Enhanced metabolic flexibility
✔ Long-term body composition improvements
GL-3 represents the most advanced tier of incretin-based therapy and is typically utilized for patients requiring longer-term, provider-directed metabolic intervention and sustained fat loss.
All GL-3 products require clinical consultation and prescription approval prior to dispensing.
🔬 Key Research-Based Mechanisms
🔥 Triple-Incretin Activation for Superior Fat Loss
Simultaneous activation of GLP-1, GIP, and glucagon receptors enhances satiety and drives adipose tissue reduction.
Jastreboff et al., 2023 (NEJM) – Demonstrated up to 24.2% total body-weight reduction over 48 weeks.
🩸 Improved Glycemic Control & Insulin Sensitivity
Reduces fasting glucose, improves insulin signaling, and lowers HbA1c.
Frias et al., 2023 (Diabetes Care) – Reported HbA1c reductions up to 2.2%.
🧠 Appetite Suppression & Craving Control
Reduces central appetite signaling and food reward pathways.
Killion et al., 2022 – Demonstrated reduced hedonic eating behavior in preclinical models.
🧬 Increased Fat Oxidation & Energy Expenditure
Glucagon receptor activation increases metabolic rate and fat utilization.
Gil-Lozano et al., 2021 – Showed preservation of metabolic rate with increased fat oxidation.
⚕️ Clinical Access & Prescription Protocol
GL-3 therapy requires provider oversight and prescription approval.
✔ Telehealth consultation required prior to dispensing
✔ Labs may be recommended (HbA1c, fasting glucose, lipid panel, CMP)
✔ Individualized dosing and titration plan
✔ Ongoing provider monitoring and follow-up included
💉 Dosing Protocol (GL-3 Core 60)
Total Dose
60mg Total GL-3
Package Contents
1 × 60mg / 5mL vial
Concentration
12mg/mL
Dosing Equivalency
| Units | GL-3 Dose |
|---|---|
| 8 Units | ~1mg |
| 17 Units | ~2mg |
| 25 Units | ~3mg |
| 33 Units | ~4mg |
| 42 Units | ~5mg |
| 50 Units | ~6mg |
| 67 Units | ~8mg |
| 83 Units | ~10mg |
Starting Dose
17 Units Weekly (~2mg)
Titration Strategy (Standard PROPeptides Protocol)
✔ Begin at 17 units weekly
✔ Maintain dose until 2 consecutive weeks of no meaningful weight loss
✔ Increase by approximately 8–9 units (~1mg) when appropriate
✔ If side effects occur, reduce dose by approximately 8–9 units and resume titration after symptoms resolve
Administration
Route: Subcutaneous injection
Preferred Site: Abdomen
Frequency: Once weekly
Ideal Use
The GL-3 Core 60 vial is designed for patients who have advanced beyond starter dosing and are maintaining moderate to higher weekly doses.
Typical utilization:
-
4mg weekly (33 units) = approximately 15 weeks
-
5mg weekly (42 units) = approximately 12 weeks
-
6mg weekly (50 units) = approximately 10 weeks
-
8mg weekly (67 units) = approximately 7–8 weeks
Actual duration varies based on provider-directed titration and individual response.
Program Length
Typically utilized as part of a 3–12 month provider-guided metabolic optimization program with reassessment every 4–8 weeks.
Compatible Stacks
KPV
Supports gut health and inflammation management.
Tesamorelin
May support body composition optimization and visceral fat reduction.
MOTS-C
Supports metabolic efficiency and insulin sensitivity.
GHK-Cu
Supports recovery and tissue support.
📦 What’s Included With Every Order
✔ 1 × 60mg / 5mL GL-3 vial
✔ Insulin syringes & alcohol swabs
✔ Sharps container bag
✔ Printed dosing, titration, storage, and injection guide
✔ Ongoing access to licensed prescribing provider
✔ Free telemedicine consultation through Arizona Sports Medicine
📧 Need Assistance?
480-400-6225
🛡️ Maximum Potency. Triple-Pathway Precision. Clinical Oversight.
GL-3 Core 60 is designed for patients seeking long-term metabolic optimization with the convenience of a high-capacity multi-dose vial. Through triple-incretin activation and provider-guided dosing, GL-3 supports meaningful fat loss, appetite control, improved insulin sensitivity, and sustained body composition improvements.
Commit to GL-3 Core 60 for advanced metabolic support, extended supply, and provider-guided weight loss optimization.
Ingredients
GL-3 Molecule (Prescription Only) – 60mg / 5mL
Triple-Incretin Therapy for Maximum Fat Loss, Appetite Control & Metabolic Optimization
Formulation
GL-3 Core 60
1 × 60mg GL-3 Multi-Dose Vial
Each vial contains:
-
60mg GL-3
-
5mL total volume
-
Concentration: 12mg/mL
Total Package Contents: 60mg GL-3 (5mL Total)
Classification: Prescription Only – Requires Provider Consultation & Approval
What Is GL-3 Therapy?
GL-3 is a prescription triple-incretin therapy that activates three key metabolic pathways:
-
GLP-1 (Glucagon-Like Peptide-1)
-
GIP (Glucose-Dependent Insulinotropic Polypeptide)
-
Glucagon Receptor
By targeting all three receptors simultaneously, GL-3 provides comprehensive metabolic signaling, leading to:
✔ Significant appetite suppression
✔ Accelerated fat loss
✔ Improved insulin sensitivity
✔ Increased energy expenditure
✔ Enhanced metabolic flexibility
✔ Long-term body composition improvements
GL-3 represents the most advanced tier of incretin-based therapy and is typically utilized for patients requiring longer-term, provider-directed metabolic intervention and sustained fat loss.
All GL-3 products require clinical consultation and prescription approval prior to dispensing.
🔬 Key Research-Based Mechanisms
🔥 Triple-Incretin Activation for Superior Fat Loss
Simultaneous activation of GLP-1, GIP, and glucagon receptors enhances satiety and drives adipose tissue reduction.
Jastreboff et al., 2023 (NEJM) – Demonstrated up to 24.2% total body-weight reduction over 48 weeks.
🩸 Improved Glycemic Control & Insulin Sensitivity
Reduces fasting glucose, improves insulin signaling, and lowers HbA1c.
Frias et al., 2023 (Diabetes Care) – Reported HbA1c reductions up to 2.2%.
🧠 Appetite Suppression & Craving Control
Reduces central appetite signaling and food reward pathways.
Killion et al., 2022 – Demonstrated reduced hedonic eating behavior in preclinical models.
🧬 Increased Fat Oxidation & Energy Expenditure
Glucagon receptor activation increases metabolic rate and fat utilization.
Gil-Lozano et al., 2021 – Showed preservation of metabolic rate with increased fat oxidation.
⚕️ Clinical Access & Prescription Protocol
GL-3 therapy requires provider oversight and prescription approval.
✔ Telehealth consultation required prior to dispensing
✔ Labs may be recommended (HbA1c, fasting glucose, lipid panel, CMP)
✔ Individualized dosing and titration plan
✔ Ongoing provider monitoring and follow-up included
💉 Dosing Protocol (GL-3 Core 60)
Total Dose
60mg Total GL-3
Package Contents
1 × 60mg / 5mL vial
Concentration
12mg/mL
Dosing Equivalency
| Units | GL-3 Dose |
|---|---|
| 8 Units | ~1mg |
| 17 Units | ~2mg |
| 25 Units | ~3mg |
| 33 Units | ~4mg |
| 42 Units | ~5mg |
| 50 Units | ~6mg |
| 67 Units | ~8mg |
| 83 Units | ~10mg |
Starting Dose
17 Units Weekly (~2mg)
Titration Strategy (Standard PROPeptides Protocol)
✔ Begin at 17 units weekly
✔ Maintain dose until 2 consecutive weeks of no meaningful weight loss
✔ Increase by approximately 8–9 units (~1mg) when appropriate
✔ If side effects occur, reduce dose by approximately 8–9 units and resume titration after symptoms resolve
Administration
Route: Subcutaneous injection
Preferred Site: Abdomen
Frequency: Once weekly
Ideal Use
The GL-3 Core 60 vial is designed for patients who have advanced beyond starter dosing and are maintaining moderate to higher weekly doses.
Typical utilization:
-
4mg weekly (33 units) = approximately 15 weeks
-
5mg weekly (42 units) = approximately 12 weeks
-
6mg weekly (50 units) = approximately 10 weeks
-
8mg weekly (67 units) = approximately 7–8 weeks
Actual duration varies based on provider-directed titration and individual response.
Program Length
Typically utilized as part of a 3–12 month provider-guided metabolic optimization program with reassessment every 4–8 weeks.
Compatible Stacks
KPV
Supports gut health and inflammation management.
Tesamorelin
May support body composition optimization and visceral fat reduction.
MOTS-C
Supports metabolic efficiency and insulin sensitivity.
GHK-Cu
Supports recovery and tissue support.
📦 What’s Included With Every Order
✔ 1 × 60mg / 5mL GL-3 vial
✔ Insulin syringes & alcohol swabs
✔ Sharps container bag
✔ Printed dosing, titration, storage, and injection guide
✔ Ongoing access to licensed prescribing provider
✔ Free telemedicine consultation through Arizona Sports Medicine
📧 Need Assistance?
480-400-6225
🛡️ Maximum Potency. Triple-Pathway Precision. Clinical Oversight.
GL-3 Core 60 is designed for patients seeking long-term metabolic optimization with the convenience of a high-capacity multi-dose vial. Through triple-incretin activation and provider-guided dosing, GL-3 supports meaningful fat loss, appetite control, improved insulin sensitivity, and sustained body composition improvements.
Commit to GL-3 Core 60 for advanced metabolic support, extended supply, and provider-guided weight loss optimization.
Disclaimer
GL-3 Molecule (Prescription Only) – 60mg / 5mL
Triple-Incretin Therapy for Maximum Fat Loss, Appetite Control & Metabolic Optimization
Formulation
GL-3 Core 60
1 × 60mg GL-3 Multi-Dose Vial
Each vial contains:
-
60mg GL-3
-
5mL total volume
-
Concentration: 12mg/mL
Total Package Contents: 60mg GL-3 (5mL Total)
Classification: Prescription Only – Requires Provider Consultation & Approval
What Is GL-3 Therapy?
GL-3 is a prescription triple-incretin therapy that activates three key metabolic pathways:
-
GLP-1 (Glucagon-Like Peptide-1)
-
GIP (Glucose-Dependent Insulinotropic Polypeptide)
-
Glucagon Receptor
By targeting all three receptors simultaneously, GL-3 provides comprehensive metabolic signaling, leading to:
✔ Significant appetite suppression
✔ Accelerated fat loss
✔ Improved insulin sensitivity
✔ Increased energy expenditure
✔ Enhanced metabolic flexibility
✔ Long-term body composition improvements
GL-3 represents the most advanced tier of incretin-based therapy and is typically utilized for patients requiring longer-term, provider-directed metabolic intervention and sustained fat loss.
All GL-3 products require clinical consultation and prescription approval prior to dispensing.
🔬 Key Research-Based Mechanisms
🔥 Triple-Incretin Activation for Superior Fat Loss
Simultaneous activation of GLP-1, GIP, and glucagon receptors enhances satiety and drives adipose tissue reduction.
Jastreboff et al., 2023 (NEJM) – Demonstrated up to 24.2% total body-weight reduction over 48 weeks.
🩸 Improved Glycemic Control & Insulin Sensitivity
Reduces fasting glucose, improves insulin signaling, and lowers HbA1c.
Frias et al., 2023 (Diabetes Care) – Reported HbA1c reductions up to 2.2%.
🧠 Appetite Suppression & Craving Control
Reduces central appetite signaling and food reward pathways.
Killion et al., 2022 – Demonstrated reduced hedonic eating behavior in preclinical models.
🧬 Increased Fat Oxidation & Energy Expenditure
Glucagon receptor activation increases metabolic rate and fat utilization.
Gil-Lozano et al., 2021 – Showed preservation of metabolic rate with increased fat oxidation.
⚕️ Clinical Access & Prescription Protocol
GL-3 therapy requires provider oversight and prescription approval.
✔ Telehealth consultation required prior to dispensing
✔ Labs may be recommended (HbA1c, fasting glucose, lipid panel, CMP)
✔ Individualized dosing and titration plan
✔ Ongoing provider monitoring and follow-up included
💉 Dosing Protocol (GL-3 Core 60)
Total Dose
60mg Total GL-3
Package Contents
1 × 60mg / 5mL vial
Concentration
12mg/mL
Dosing Equivalency
| Units | GL-3 Dose |
|---|---|
| 8 Units | ~1mg |
| 17 Units | ~2mg |
| 25 Units | ~3mg |
| 33 Units | ~4mg |
| 42 Units | ~5mg |
| 50 Units | ~6mg |
| 67 Units | ~8mg |
| 83 Units | ~10mg |
Starting Dose
17 Units Weekly (~2mg)
Titration Strategy (Standard PROPeptides Protocol)
✔ Begin at 17 units weekly
✔ Maintain dose until 2 consecutive weeks of no meaningful weight loss
✔ Increase by approximately 8–9 units (~1mg) when appropriate
✔ If side effects occur, reduce dose by approximately 8–9 units and resume titration after symptoms resolve
Administration
Route: Subcutaneous injection
Preferred Site: Abdomen
Frequency: Once weekly
Ideal Use
The GL-3 Core 60 vial is designed for patients who have advanced beyond starter dosing and are maintaining moderate to higher weekly doses.
Typical utilization:
-
4mg weekly (33 units) = approximately 15 weeks
-
5mg weekly (42 units) = approximately 12 weeks
-
6mg weekly (50 units) = approximately 10 weeks
-
8mg weekly (67 units) = approximately 7–8 weeks
Actual duration varies based on provider-directed titration and individual response.
Program Length
Typically utilized as part of a 3–12 month provider-guided metabolic optimization program with reassessment every 4–8 weeks.
Compatible Stacks
KPV
Supports gut health and inflammation management.
Tesamorelin
May support body composition optimization and visceral fat reduction.
MOTS-C
Supports metabolic efficiency and insulin sensitivity.
GHK-Cu
Supports recovery and tissue support.
📦 What’s Included With Every Order
✔ 1 × 60mg / 5mL GL-3 vial
✔ Insulin syringes & alcohol swabs
✔ Sharps container bag
✔ Printed dosing, titration, storage, and injection guide
✔ Ongoing access to licensed prescribing provider
✔ Free telemedicine consultation through Arizona Sports Medicine
📧 Need Assistance?
480-400-6225
🛡️ Maximum Potency. Triple-Pathway Precision. Clinical Oversight.
GL-3 Core 60 is designed for patients seeking long-term metabolic optimization with the convenience of a high-capacity multi-dose vial. Through triple-incretin activation and provider-guided dosing, GL-3 supports meaningful fat loss, appetite control, improved insulin sensitivity, and sustained body composition improvements.
Commit to GL-3 Core 60 for advanced metabolic support, extended supply, and provider-guided weight loss optimization.